Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 14/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3049941 | 0.89 | NTSR1 (0.45) | NTSR1SLC2A1LMNAKMT2APDE10A | |
| SCHEMBL3046918 | 0.85 | PDE10A (0.53) | NTSR1SLC2A1LMNAKMT2APDE10A | |
| SCHEMBL3057939 | 0.85 | GPR6 (0.43) | LMNAKMT2APDE10A | |
| SCHEMBL3056812 | 0.84 | EHMT2 (0.40) | NTSR1LMNAKMT2AGRM2 | |
| SCHEMBL3042364 | 0.82 | PDE10A (0.36) | NTSR1SLC2A1LMNAKMT2APDE10A | |
| SCHEMBL3052033 | 0.82 | PDE10A (0.41) | NTSR1SLC2A1LMNAKMT2APDE10A | |
| SCHEMBL3055190 | 0.81 | NTSR1 (0.41) | NTSR1LMNAKMT2APDE10A | |
| SCHEMBL3049868 | 0.81 | LMNA (0.42) | NTSR1LMNAKMT2APDE10AGRM2 | |
| SCHEMBL3052995 | 0.80 | PDE10A (0.49) | NTSR1LMNAKMT2APDE10A | |
| SCHEMBL3062919 | 0.80 | DRD2 (0.45) | LMNAKMT2APDE10AGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222353-A1 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-09-02 | — | — | US | claimed |
| EP-1981868-A2 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | Pfizer Products Inc. (US) | 2008-10-22 | — | — | EP | claimed |
| WO-2007085954-A2 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-08-02 | — | — | WO | claimed |
| US-20100222353-A1 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-09-02 | — | — | US | disclosed |
| EP-1981868-A2 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | Pfizer Products Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007085954-A2 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222353-A1 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | PDE12, PDE5A, PDE2A | NTSR1 2789/4885SLC2A1 4451/4885LMNA 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.